Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05257655
Other study ID # 0815-2021
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 9, 2023
Est. completion date October 1, 2023

Study information

Verified date October 2023
Source Klinikum Klagenfurt am Wörthersee
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The blockade of the superior cervical ganglion (GCS) of the sympathetic trunk is a very special form of therapy. The transoral blocking technique, also known as GLOA (ganglionic local opioid analgesia), is very suitable for achieving GCS. A total of 5 μg of sufentanil in 2 ml of sodium chlorid are applied. Since no imaging evidence of the injected substances has been published for a GLOA in a living person, it is planned to carry out an MRI examination immediately after the ganglionic local opioid analgesia in order to show the spread and distribution pattern of the injected substance. It is also planed to show a correlation of the spread of the injected substance with the efficacy of the intervention. To determine the interrater reliability, the GLOA is carried out alternately by 2 different examiners and the existing MRI images of the GLOA are assessed by an radiologist and anatomist in a blinded manner. In a follow-up after 1 and 3 months, the questionnaires and pain scores are evaluated again.


Description:

The blockade of the superior cervical ganglion (GCS) of the sympathetic trunk is a very special form of therapy. It is successfully used for numerous, often protracted diseases that severely impair the patient's quality of life, such as idiopathic facial pain syndromes or trigeminal neuralgia. The transoral blocking technique, also known as GLOA (ganglionic local opioid analgesia), is very suitable for achieving GCS. With this technique, a Sprotte cannula is inserted into the pharyngeal recess (Rosenmueller) located behind the palatopharyngeal arch and pierced through the pharyngeal wall into the parapharyngeal space. A total of 5 μg of sufentanil in 2 ml of sodium chlorid are applied. Since no imaging evidence of the injected substances has been published for a GLOA in a living person, it is planned to carry out an MRI examination immediately after the ganglionic local opioid analgesia in order to show the spread and distribution pattern of the injected substance. It is also planed to show a correlation of the spread of the injected substance with the efficacy of the intervention. For this, different questionnaires (NRS, quality of life, sleep quality, patient satisfaction) are carried out before and after the intervention. To determine the interrater reliability, the GLOA is carried out by 2 different examiners and the existing MRI images of the GLOA are assessed by an radiologist and anatomist in a blinded manner. In a follow-up after 1 and 3 months, the questionnaires and pain scores are evaluated again.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date October 1, 2023
Est. primary completion date August 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Trigeminal neuralgia - Postherpetic neuralgia - Glossopharyngeal neuralgia - Atypical facial pain Exclusion Criteria: - psychosis - language barrier - Pregnant and breastfeeding women - Seizure disorders (epilepsy) - Increased risk of bleeding

Study Design


Intervention

Procedure:
MRI after ganglionic local opioid analgesia (GLOA)
MRI after Ganglionic Local Opioid Analgesia at the Ganglion Cervicale Superius

Locations

Country Name City State
Austria Klinikum Klagenfurt am Wörthersee Klagenfurt

Sponsors (2)

Lead Sponsor Collaborator
Klinikum Klagenfurt am Wörthersee University of Klagenfurt

Country where clinical trial is conducted

Austria, 

References & Publications (2)

Feigl G, Rosmarin W, Likar R. [Block of the superior cervical ganglion of the Truncus sympathicus. Why it often is not possible!]. Schmerz. 2006 Aug;20(4):277-80, 282-4. doi: 10.1007/s00482-005-0435-6. German. — View Citation

Spacek A, Bohm D, Kress HG. Ganglionic local opioid analgesia for refractory trigeminal neuralgia. Lancet. 1997 May 24;349(9064):1521. doi: 10.1016/S0140-6736(05)62101-0. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Distribution of the injected fluid in the area of the superior cervical ganglion MRI verified distribution of the injected fluid in the area of the superior cervical ganglion immediately after the intervention
Secondary Quality of life questionnaire The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state (https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/) Before first and after last GLOA. After 1 and 3 month (follow up)
Secondary Pain assessed by NRS Present pain intensity on a 0-10 Numerical Rating Scale (NRS) with 0 corresponding to "no pain" and 10 to "the worst pain imaginable baseline, immediately after intervention, After 1 and 3 month (follow up)
Secondary Patient satisfaction assessed by satisfaction questionaire ZUF-8 is a measuring instrument for the global, one-dimensional recording of patient satisfaction. It is the German-language adaptation of the American CSQ-8 by Attkisson & Zwick (1982). General satisfaction ("general satisfaction") with aspects of the clinic or the treatment received is recorded using eight items. ZUF-8 is particularly suitable for an economical screening of patient satisfaction. Before first and after last GLOA. After 1 and 3 month (follow up)
Secondary Sleep quality assessed by sleep quality questionnaire To record the sleep quality the questionnaire on sleep quality is carried out (PSQI) Before first and after last GLOA. After 1 and 3 month (follow up)
Secondary Efficacy prediction based on MRI verified fluid spread Efficacy prediction based on the MRI verified fluid spread in millimeter in the area of the superior cervical ganglion immediately after the intervention
See also
  Status Clinical Trial Phase
Completed NCT04158752 - Anti-CGRP for Inflamation and Pain Modulation in Small Fiber Neuropathy/Fibromyalgia Phase 4
Terminated NCT02321566 - Motor Cortex Stimulation for the Treatment of Chronic Facial, Upper Extremity, and Throat Pain. Phase 1